Comparing the effects of travoprost and brinzolamide on intraocular pressure after phacoemulsification

Abstract

Purpose To evaluate the intraocular pressure (IOP) lowering effect of travoprost and brinzolamide within the first 24 h after phacoemulsification cataract surgery. Methods This prospective, randomized, double-masked, controlled study comprised 90 eyes of 90 consecutive patients with senile cataract who had uneventful phacoemulsification surgery. Eyes in the first group received travoprost 0.0015%, second group received brinzolamide 1%. Eyes in the third group received balanced salt solution and were used as control. One drop was instilled immediately after surgery. IOP was measured 24 h preoperatively, 6 and 24 h postoperatively. Analysis of variance, Student's-t and w 2 -tests were used for statistical analyses. Results Preoperatively IOP was not significantly different among the three groups (P ¼ 0.653). At 6 and 24 h postoperatively IOP was lower in both travoprost and brinzolamide group when compared to control group (P ¼ 0.018 and 0.015 at 6 h, P ¼ 0.010 and 0.012 at 24 h, respectively). The difference between travoprost and brinzolamide group was not significant (P ¼ 0.859 at 6 h and P ¼ 0.581 at 24 h). Both travoprost and brinzolamide significantly reduced IOP increases when compared to control eyes at 6 and 24 h (P ¼ 0.036 and 0.029 at 6 h, P ¼ 0.010 and 0.007 at 24 h, respectively). The difference in IOP increase at 6 and 24 h between travoprost and brinzolamide group was not significant (P ¼ 0.744 at 6 h and P ¼ 0.672 at 24 h). Conclusion Both travoprost and brinzolamide significantly lowered IOP after small incision phacoemulsification cataract surgery within the first 24 h without any side effect.

Safety of repeated topical ocular administration of a polycarbophil-based formulation in several models of ocular surgery in rabbits

“…The addition of the carbomers to the ocular formulation has not been associated with adverse reaction when used perioperatively. [17][18][19][20] In fact, Vexol (rimexolone, carbomer 934P) is specifically approved for the treatment of anterior chamber inflammation after cataract surgery. 21 Furthermore, carbomer-based ocular lubricants (Viscotears, Celluvisc) may be safer to use in post-LASIK patients with dry eyes than noncarbomer-based ocular lubricants to prevent flap dislocation because the shearthinning property provides a lower coefficient of friction.…”

Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy

“…It is effective in the short-and long-term treatment of patients with glaucoma or ocular hypertension and in reducing IOP after phacoemulsification cataract surgery. [10][11][12][13] Apraclonidine reduces IOP by reducing aqueous production and increasing uveoscleral outflow. 19 However, the uveoscleral outflow effect occurs only with prolonged treatment.…”

“…8,9 It is effective in the short-and long-term treatment of patients with glaucoma or ocular hypertension and in reducing IOP after phacoemulsification cataract surgery. [10][11][12][13] To our knowledge, there are no published reports of the effectiveness of brinzolamide in preventing IOP elevation after laser treatment. This study examined the IOPlowering effects of brinzolamide 1% and apraclonidine 0.5% for prophylaxis of IOP elevation after Nd:YAG laser posterior capsulotomy.…”

Early Post-Operative Complications in Cataract Surgery

“…Nearly all patients' pressures returned to baseline with or without treatment. Some individuals, however, may experience pain, corneal oedema, glaucomatous nerve damage, or anterior ischemic optic neuropathy (Ermis et al, 2005). Elevated pressure is the most frequent postoperative complication demanding treatment following phacoemulsification (Hildebrand et al, 2003).…”